Biotech

All Articles

Pfizer takes $230M reached after axing failed DMD gene therapy

.Pfizer's phase 3 Duchenne muscle dystrophy (DMD) genetics therapy breakdown has blown a $230 millio...

AC Immune observes 'landmark' prospective in Alzheimer's medicine information

.After much more than two decades of work on neurodegenerative illness, Swiss biotech AC Invulnerabl...

GSK drops ph. 2 HPV vaccination over lack of best-in-class potential

.GSK has actually scrapped a period 2 individual papillomavirus (HPV) vaccine from its own pipeline ...

OS Therapies refiles $6M IPO to fund HER2 drug, preclinical ADCs

.OS Therapies will definitely provide on the NYSE American stock substitution this morning via a $6....

ALX's fizzling CD47 response cost sends supply spiraling down

.ALX Oncology's stage 2 stomach cancer cells reaction cost has compromised. After observing its CD47...

Ionis axes eye condition coming from aim ats of Roche-partnered prospect after records let down

.Another of Ionis Pharmaceuticals' key midphase readouts has actually disappointed expectations, urg...

Biogen's chief executive officer said no dangerous deals in 2023. He's ready to be bold

.While Biogen's pharma peers are searching for late-stage resources with little bit of risk, CEO Chr...

Instil refills pipe in $2B biobucks handle ImmunOnco

.Instil Bio has been actually a biotech looking for a pipeline after it ditched its lead resources o...

Biogen leaves Denali Alzheimer's collab

.Biogen has actually returned civil liberties to a very early Alzheimer's ailment program to Denali ...

Takeda faucets brand new mind people oncology service-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of substantial leadership hirings, firings ...